Literature DB >> 7438460

Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy).

F Pacini, A Pinchera, C Giani, L Grasso, L Baschieri.   

Abstract

Measurements of circulating thyroglobulin (hTg) and 131I whole body scan were performed in 101 patients with differentiated thyroid carcinoma who had been subjected to surgical thyroidectomy and 131I ablation of remaining thyroid tissue. All 45 patients with positive scans (i.e. functioning metastases) had elevated hTg concentrations. Of fifty-six patients with negative scans forty-two had undetectable or very low hTg levels and were considered to be free of metastatic thyroid tissue, whereas fourteen showed the presence of non-functioning metastases in the clinical and/or radiological examination. In this group of patients, eleven had elevated serum hTg levels while the other three patients had detectable hTg concentrations within the normal range. These results indicate that serum hTg measurements correlate very well with scan findings and have the added advantage of detecting non-functioning metastases which would not be detected by scanning. We concluded that measurement of serum hTg may be used together with scanning, as the first step in the follow-up of thyroidectomized patients with differentiated thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438460     DOI: 10.1111/j.1365-2265.1980.tb01030.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

Review 1.  The use of recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer.

Authors:  M C Skarulis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Thyroid incidentaloma.

Authors:  Seema Singh; Anutosh Singh; A K Khanna
Journal:  Indian J Surg Oncol       Date:  2011-11-23

Review 3.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

Review 4.  Post-surgical follow-up of differentiated thyroid cancer.

Authors:  F Pacini; R Elisei; L Fugazzola; F Cetani; C Romei; F Mancusi; A Pinchera
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

5.  The value of serum thyroglobulin measurement as a marker of cancer recurrence in the follow-up of patients previously treated for differentiated thyroid tumor.

Authors:  E Roti; G Robuschi; R Emanuele; P Bandini; A Russo; P Riva; E Galassi; U P Guerra; A Manfredi; A Bozzetti; A M Guazzi; A Gnudi
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

6.  Comparison of serum thyroglobulin with iodine scans in thyroid cancer.

Authors:  M A Charles
Journal:  J Endocrinol Invest       Date:  1982 Jul-Aug       Impact factor: 4.256

7.  I-131 therapy for thyroglobulin positive patients without anatomical evidence of persistent disease.

Authors:  N Kamel; D Corapcioglu; M Sahin; A Gürsoy; O Küçük; G Aras
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

8.  Serum thyroglobulin determinations in the differential diagnosis of congenital hypothyroidism.

Authors:  F Pacini; R Lari; P La Ricca; L Grasso; F Di Bartolo; G F Fenzi; M Ciampi; S G Gragnani; L Baschieri; A Pinchera
Journal:  J Endocrinol Invest       Date:  1984-02       Impact factor: 4.256

9.  Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer.

Authors:  D Grammatopoulos; Y Elliott; S C Smith; I Brown; R J Grieve; E W Hillhouse; M A Levine; M D Ringel
Journal:  Mol Pathol       Date:  2003-06

10.  Immunoreactive thyroglobulin in sera and saliva of patients with various thyroid disorders: role of autoantibodies.

Authors:  A J Van Herle; P D Rosenblit; T L Van Herle; P Van Herle; M Greipel; K Kellett
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.